Hi Tony
I am well aware it is an opinion game but I was asked to provide my numbers. Hence the importance of the % chance of success which as I have stated is the single most important variable. If all indications become commercial the share price will be well north of $264 the model attempts to take this into account.
As for % chance of PMS gaining FDA approval from here I beg to differ. Yes you can quote 53% of positive phase 2 results progressing to phase 3 success, but show me a compound with the animal models NNZ- 2591 has, the strength and consistency of the PMS phase 2 results, the statistical significance/power generated by 18 subjects in an area of medicine where there is no approved treatment and any improvement is seen as significant PLUS a similar first in class molecule performing admirably in a similar condition - and I will show you a compound with a COS much closer to 100% than 50%.
IMO but this is actually my wheelhouse in the real world.
Hi TonyI am well aware it is an opinion game but I was asked to...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.56 |
Change
-0.400(2.67%) |
Mkt cap ! $1.860B | |||
| Open | High | Low | Value | Volume |
| $14.96 | $15.00 | $14.18 | $7.303M | 503.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 30783 | $14.55 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.60 | 1006 | 1 |
View Market Depth
| Last trade - 16.10pm 03/10/2024 (20 minute delay) ? |
| NEU (ASX) Chart |